Immunology Investor Event

Dupixent: Atopic Dermatitis Adolescents 12-17yo Prevalence Treated Moderate-to-Severe Number of patients (thousands) 2,497 2,072 968 1,015 1,983 Biologics eligible 389 345 734 2,297 2,538 4,369 5,035 Moderate-to-Severe uncontrolled sanofi Most in need 166 92 258 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 5,500 Treated with multiple systemic steroids or one immunosuppressant or phototherapy (2) US Europe (1) Source: Sanofi analysis (1) Germany, France, Italy, Spain & United Kingdom. (2) For Europe, patients who have inadequate response or intolerant to immunosuppressants 3 Immunology Investor Event

View entire presentation